Original Title: Notice from the Office of the People’s Government of Dangtu County on Issuing the “Several Policies for Promoting the Development of the Life and Health Industry in Dangtu County (Revised)”

To accelerate the high-quality development of the life and health industry in Dangtu County, promote the clustering of the life and health industry, strengthen the county’s life and health industry, and foster new drivers of economic growth, the following policy measures are hereby formulated.

Article 1: The life and health industries prioritized for development in our county include, but are not limited to:

Biopharmaceutical Industry: Emerging biotechnologies such as stem cells, neoantigen discovery, tissue engineering, and peptide synthesis; traditional Chinese medicine preparations and chemical drugs; high-end medical devices and consumables, such as rapid diagnostic test kits, biological culture media, and substitutes for imported medical devices and reagents.

Health and Wellness Industry: Smart rehabilitation, elderly care and wellness, smart wearables, health care products, nutritional foods, health foods, nutritional supplements, cosmeceuticals, and health-oriented daily chemicals.

Article 2: Establishment of an Industrial Development Fund. Through industrial fund guidance, equity investment, and other means, priority support shall be provided for the research, development, and production of biopharmaceutical and medical device projects.

Article 3: Investment Subsidies for Newly Introduced Projects. Projects with a total investment of 100 million yuan or more (excluding land costs) and an investment intensity per mu of no less than 2 million yuan shall be granted an investment subsidy equivalent to 2% of the enterprise’s actual investment. Based on a comprehensive evaluation of factors such as project investment scale, industry advantages, product influence, and actual contributions to the local area, the subsidy ratio may be appropriately increased, generally not exceeding 5%.Major projects with a total investment of 1 billion yuan (excluding land costs) or more may be considered on a case-by-case basis.

Article 4: Support for Accelerated Development During the Start-up Phase. Based on the enterprise’s contribution to the local economy through its main business revenue in the current year, a certain amount of operational incentive will be provided to the enterprise in annual installments. The duration generally shall not exceed 5 years, and for particularly major projects, it shall not exceed 10 years.

Article 5: Interest Subsidies for Major Project Loans. For construction-phase loans of major life sciences and healthcare projects with a total investment of 200 million yuan or more (excluding land costs), appropriate interest subsidies shall be provided to enterprises based on the actual loan interest (referencing the People’s Bank of China’s benchmark lending rate for the same period) in accordance with the principle of mutual commitment; for projects with a total investment of 500 million yuan or more (excluding land costs), the subsidy ratio may be appropriately increased. The subsidy period shall not exceed two years, and the total subsidy amount shall not exceed 20 million yuan.

Article 6: Factory Rent Subsidies. Following the principle of “pay first, receive subsidy later,” manufacturing enterprises that move into standard factory buildings shall be granted a certain rent subsidy based on the agreed-upon per-mu economic benefit.

Article 7: Subsidy for the Purchase of Key Equipment. For biopharmaceutical and medical device projects that comply with relevant provincial and municipal policies and have a total actual investment of 100 million yuan or more (excluding land costs), a subsidy of 5% of the original value of key equipment purchased in the current year shall be provided. For projects with a total investment of 200 million yuan or more (excluding land costs), the subsidy ratio may be appropriately increased. The total fiscal subsidy from all levels of government for a single project shall not exceed 30 million yuan.

Article 8: Cleanroom Construction Subsidies. For enterprises constructing new clean production workshops, renovation subsidies of 100 yuan, 300 yuan, 500 yuan, and 1,000 yuan per square meter will be provided according to four tiers: Class 100,000, Class 10,000, Class 1,000, and Class 100. Laboratories and shielded rooms will receive subsidies based on the Class 100,000 and Class 10,000 standards for production facilities, respectively.

Article 9: Support for the Introduction and Establishment of Top 100 Enterprises. For enterprises ranked among the national top 100 in the pharmaceutical industry that establish their headquarters in this county, a one-time subsidy of 500,000 yuan will be provided in addition to the provincial subsidy.

Article 10: Encouraging R&D and Certification of Medical Devices. For companies that obtain Class II or Class III medical device registration certificates and commence production in this county, a subsidy of 50% of the actual R&D costs will be provided, with maximum subsidies of 1 million yuan and 5 million yuan, respectively.For newly obtained production approvals for innovative drugs, improved drugs, and generic drugs, a subsidy of 5 million yuan, 3 million yuan, or 1 million yuan, respectively, will be provided on top of the provincial subsidy for each drug production approval obtained (multiple specifications of the same variety are grouped as a single drug under the generic name) and industrialized in this county.For products that obtain international registration approvals and are manufactured in our county, a reward of 300,000 yuan will be granted for each product’s international registration approval, in addition to the provincial subsidy.

For solid dosage forms and injectables that pass the bioequivalence evaluation for generic drugs, subsidies of up to 6 million yuan and 1.2 million yuan, respectively, will be provided per product. Additionally, products that are among the first three of their kind nationwide to pass the bioequivalence evaluation will receive an additional reward of up to 1.2 million yuan. The maximum annual subsidy per enterprise is 15 million yuan.

Article 11: Support for New Drug R&D. For new drugs—including chemical drugs, biological products, traditional Chinese medicines, and natural medicines—that undergo clinical trials and are commercialized in this county, phased awards and subsidies will be provided based on their R&D progress:

For innovative drugs (including those approved for emergency use), those newly entering Phase I, II, or III clinical trials will receive subsidies of up to 6 million yuan, 12 million yuan, and 24 million yuan, respectively, based on 50% of the enterprise’s actual R&D investment. The annual cap per enterprise is 60 million yuan.For improved new drugs, those newly entering Phase I, II, or III clinical trials will receive subsidies of up to 4.8 million yuan, 9.6 million yuan, and 18 million yuan, respectively, based on 50% of the enterprise’s actual R&D investment, with an annual cap of 36 million yuan per enterprise.

Article 12: For leading-brand pharmaceuticals registered for production and sale in this county through transfer, support shall be provided at 50% of the actual transfer cost or appraised value of the product. Support for a single product shall not exceed 30 million yuan.

Article 13: Innovative drugs that meet eligibility criteria, are reasonably priced, and possess independent intellectual property rights, as well as generic drugs that have passed bioequivalence evaluation, are encouraged to actively participate in the review process for inclusion in the medical insurance directory. Medical devices not yet included in the provincial medical insurance directory shall be prioritized for recommendation for inclusion in the municipal procurement filing scope; eligible innovative products shall be prioritized for recommendation for inclusion in the municipal medical insurance medical consumables directory.

Article 14: Enterprises are encouraged to scale up operations. Pharmaceutical manufacturers will receive a subsidy of 1 million yuan for each milestone reached when the annual sales revenue of a single product first exceeds 100 million yuan, 500 million yuan, 800 million yuan, or 1 billion yuan.

Article 15: Support the recruitment of scientific and technological talent and management teams. For high-level scientific and technological talent teams selected through provincial screening, enterprises will receive initial support of 5 million yuan, 3 million yuan, or 1.5 million yuan, categorized into three tiers. At the same time, active support will be provided for applying for corresponding provincial and municipal policies. For various types of urgently needed talent recruited on a full-time basis by enterprises, active support will be provided for applying for provincial and municipal key talent projects; where eligible, corresponding subsidies will be granted in accordance with provincial and municipal talent policies.

Article 16: Where a single enterprise receives financial support from multiple levels of government for the same matter, except as otherwise specified by policy, the enterprise shall be awarded the difference between the highest and lowest amounts received, and no duplicate rewards shall be granted. Reward funds shall be borne in accordance with the current fiscal system.

Article 17: The County Development and Reform Commission and the County Investment Promotion Center, in conjunction with relevant departments, shall be responsible for interpreting this policy.

Article 18. Life and health projects that comply with national industrial policies and align with the county’s leading industries may be implemented in accordance with this policy upon approval. This policy shall take effect on the date of issuance and remain valid for five years, subject to timely adjustments based on higher-level policies. The original “Several Policies on Promoting the Development of the Biomedical (Health) Industry in Dangtu County (Trial)” (Dang Zheng Ban [2020] No. 29) is hereby repealed.